June 11, 2025

“OLLIE gives pharmaceutical companies a more honest view of the emotional and behavioral realities that shape adherence, grounded not in assumptions but in patients’ own words.” – Michael Oleksiw, Chief Executive Officer at Pleio 

May 22, 2025

Drug Store News features Pleio’s report revealing loneliness as a major barrier in chronic care. With 74% of patients reporting that loneliness negatively affects their physical health, the study highlights the need for peer support to improve outcomes and patient engagement.

May 22, 2025

Medication non-adherence costs the U.S. $500B annually. Pleio’s new AI, OLLIE, identifies emotional barriers through patient conversation analysis, empowering human supporters to intervene with empathy and improve outcomes.

WE PUT PRIVACY FIRST. GOODSTART® IS A FULLY TESTED, HIGHLY RELIABLE, TCPA, SOC 2 TYPE 2 CERTIFIED, AND HIPAA COMPLIANT MEDICATION SUPPORT PROGRAM.

Patient data is strictly used to support patients to take medications as prescribed by their healthcare professional.

CONTACT   |   PRIVACY   |   SUPPLIER CONDUCT   |  CAREERS

© 2025 Pleio, Inc All rights reserved.